Disclosed herein is a compound of formula (I), which is ammonium salt of GW5074,wherein R1, R2, and R3are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl； or R1, R2, R3and the nitrogen are taken together to form a 6-membered heterocyclyl； and the alkyl, the alkenyl, the alkynyl, the aryl, the heteroaryl, or the 6-membered heterocyclyl is optionally substituted with at least one substituent selected from the group consisting of, -OH, -NH2, and -NRaRb, in which Raand Rbare independently alkyl, aryl, or heteroaryl. Also disclosed herein is a pharmaceutical kit for the treatment of cancers. The pharmaceutical kit includes, a fist formulation comprising a c-Raf inhibitor and a pharmaceutically acceptable carrier； and a second formulation comprising the compound of formula (I) and a pharmaceutically acceptable carrier.本揭示內容是關於一種式(I)化合物，其是GW5074之銨鹽，其中，R1、R2及R3個別是氫、烷基、烯基、炔基、芳基或雜芳基；或是R1、R2、R3及氮合併形成一6員的雜環基；以及非必要地，可以至少一取代基來取代該烷基、該烯基、該炔基、該芳基、該雜芳基或該6員的雜環基，其中該取代基選自由–OH、–NH2及–NRaRb所組成的群組，其中Ra及Rb個別是烷基、芳基或雜芳基。本揭示內容亦是關於一種用以治療癌症的藥學套組。該藥學套組包括，一第一製劑，包含一種c–Raf抑制劑及一藥學上可接受的載體；以及一第二製劑，包含該式(I)化合物及一藥學上可接受的載體。
